-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, L0IM1HnAU7H9N0LKWtGHvZedmVs0AWPa4IirmnYT4OjNaEJlF85KSJl4bCxskekg yk2tJ+qav42YUHcrhm+4IQ== 0001246360-10-002885.txt : 20100804 0001246360-10-002885.hdr.sgml : 20100804 20100804154508 ACCESSION NUMBER: 0001246360-10-002885 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100802 FILED AS OF DATE: 20100804 DATE AS OF CHANGE: 20100804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MEDTRONIC INC CENTRAL INDEX KEY: 0000064670 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 410793183 STATE OF INCORPORATION: MN FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 710 MEDTRONIC PKWY STREET 2: MS LC300 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 BUSINESS PHONE: 7635144000 MAIL ADDRESS: STREET 1: 710 MEDTRONIC PKWY CITY: MINNEAPOLIS STATE: MN ZIP: 55432 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: COYLE MICHAEL J CENTRAL INDEX KEY: 0001233311 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-07707 FILM NUMBER: 10990942 MAIL ADDRESS: STREET 1: ONE LILLEHEI PLAZA CITY: ST. PAUL STATE: MN ZIP: 53717 4 1 form.xml PRIMARY DOCUMENT X0303 4 2010-08-02 false 0000064670 MEDTRONIC INC MDT 0001233311 COYLE MICHAEL J 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 false true false false EVP & Group Pres, Cardiology Common Stock 3738.526 I by spouse Common Stock 250 I by family trust Common Stock 2010-08-02 4 A false 17773 0 A 35342.842 D Employee Stock Option (right to buy) 37.53 2010-08-02 4 A false 70984 0 A 2011-08-02 2020-08-02 Common Stock 70984 70984 D This balance increased by 187.842 due to exempt transaction such as dividend reinvestment and dividend equivalent credits. The restrictions on these restricted stock units shall lapse on the third anniversary of the grant date if the company's cumulative diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2013 equals or exceeds a 5% compound annual growth rate, as determined by the Compensation Committee. These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Rhonda L. Ingalsbe, Attorney-in-fact 2010-08-04 -----END PRIVACY-ENHANCED MESSAGE-----